Fairvalue-Calculator Fairvalue-Calculator
EN DE

CareRay Digital Medical Technology Co (688607) Fair Value & Analysis

Healthcare · CN · Market cap 4.9B CNY

Price¥51.50
Fair Value¥43.62
Upside-15.3%
Quality95/100
Evidence: Low Range ¥32.71 – ¥54.52

Analysis

CareRay Digital Medical Technology Co (688607) currently trades at ¥51.50, while our model-based Fair Value estimate is ¥43.62 — implying the stock looks roughly 15.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

CareRay Digital Medical Technology Co., Ltd. engages in research and development, production, and sales of digital X-ray flat panel detectors in China. The company offers Gen3 panels; radiography products, including wireless, tethered, and specialized panels, as well as accessories; mammography, fluoroscopy, dental, and industrial NDT products; and custom panels. It also provides solutions for retrofit and OEMS; precision low dose care; dynamic DR; and customized solutions. The company's products are used for clinical examinations, such as medical radiographs, breast examinations, fluoroscopy, and pet medical treatment, as well as treatment of radiotherapy and interventional surgery. CareRay Digital Medical Technology Co., Ltd. was founded in 2007 and is headquartered in Suzhou, China.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABTT34) -83% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -81% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.